Ireland· IE-PA-PA0800/013/001
Berinert 500 IU Powder and solvent for solution for injection/infusion.
A c1-inhibitor, plasma derived product containing c1 esterase inhibitor (human), registered in Ireland by CSL Behring GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
C1-inhibitor, plasma derived is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AC01 (c1-inhibitor, plasma derived), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
C1-inhibitor, plasma derived · ATC B06AC01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- C1 Esterase Inhibitor (Human)
- Manufacturer
- CSL Behring GmbH
- Country
- Ireland (IE)
- ATC code
- B06AC01
- ATC class
- C1-inhibitor, plasma derived
- Defined daily dose
- 1.4 TSD, E
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA0800/013/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
47 interactions on record for c1-inhibitor, plasma derived.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
C1-inhibitor, plasma derived · interactions on record
47 records
- 5 severe
- 42 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
C1-inhibitor, plasma derived in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBerinert 500 IUCSL Behring
- NorwayBerinertCSL Behring GmbH
- SwedenBerinert 500 IE Pulver och vätska till injektions-/infusionsvätska, lösningCSL Behring GmbH
- CzechiaBERINERTCSL Behring GmbH, Marburg
- United KingdomBerinert 1,500unit powder and solvent for solution for injection vialsCSL Behring UK Ltd
- IcelandBerinertCSL Behring GmbH*
- CanadaBERINERT 1500CSL BEHRING CANADA INC
- GermanyBerinertCsl Behring Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Berinert
- Belgium · Berinert
- Bulgaria · Беринерт
- Cyprus · Berinert
- Czechia · Berinert
- Germany · Berinert
- Denmark · Berinert
- Estonia · Berinert Iv, Berinert Sc
- Spain · Berinert
- Finland · Berinert
- France · Berinert
- United Kingdom (Northern Ireland) · Berinert
- Greece · Berinert
- Croatia · Berinert
- Hungary · Berinert
- Iceland · Berinert, Cinryze
- Italy · Berinert
- Liechtenstein · Cinryze
- Lithuania · Human C1-Esterase Inhibitor Csl Behring
- Luxembourg · Berinert
- Malta · Berinert
- Netherlands · Berinert
- Norway · Berinert, Cinryze
- Poland · Berinert
- Portugal · Berinert
- Romania · Berinert
- Sweden · Berinert
- Slovenia · Berinert
- Slovakia · Berinert
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a6be8eb1-754b-4bd2-b59a-d5a2912403a8 GET /v1/drugs/a6be8eb1-754b-4bd2-b59a-d5a2912403a8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"B06AC01"
],
"strength": null,
"pa_number": "PA0800/013/001",
"substances": [
"C1 Esterase Inhibitor (Human)"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "27/08/2021",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about c1-inhibitor, plasma derived.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.